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2. Initial hypothesis and objectives 
 
The main hypothesis to be contrasted with this project is 
the next one: it is possible to produce a vaccine against 
Mycoplasma hyopneumoniae infection using an inactivated 
form of the pathogen, leading this way to an immune 
response able to develop an effective, but not fully, 
protection in pigs. In order to be able to demonstrate this 
hypothesis, it will be needed: 
 
1.To study and understand the mechanism of infection of 
Mycoplasma     hyopneumoniae. 
2.To know the main types of vaccines and their 
characteristics and to relate this knowledge to the available 
information about  the pathogen. 
3.Once knowledge about the subject has been 
consolidated, to develop a feasible vaccine according to 
prior art. 
4.To design an experiment capable of testing the effect of 
the vaccine in vivo. 
 
1. Introduction 
 
Mycoplasma hyopneumoniae is the etiologic agent of 
enzootic pneumonia in swine. Enzootic pneumonia is a 
chronic disease that is an important cause of economic loss 
in the swine industry due to reduced weight gain and poor 
feed efficiency of host. The microorganism causes a 
chronic cough, dull hair coat, retarded growth and 
predisposition to secondary infections. The disease has 
almost no mortality but high morbidity. 
 
M. hyopneumoniae attaches primarily to the ciliated 
epithelium of the trachea, bronchi and bronchioles. This 
attachment is a prerequisite for initiation of the infection. 
The colonization of the mucosal clearance by M. 
hyopneumoniae results in ciliostasis (disruption of the cilia 
on the epithelial surface).  The microorganism modulates 
the immune system of the respiratory tract by altering 
alveolar macrophage function and lymphocyte function. 
This immonomodulation is the main responsible of 
ciliostasis and results in a significant reduction of the 
efficiency of protection against invading respiratory 
pathogens. The bronchopneumonia caused by coinfection 
of M. hyopneumoniae as primary pathogen and other 
bacteria as secondary pathogens is known as enzootic 
pneumonia. 
 
 
 
 
 
 
 
 
Vaccination with commercial bacterins has become an 
important tool to control M. hyopneumoniae infections. 
These vaccines, produced from adjuvanted whole-cell or 
membrane preparations, are commonly used to induce 
partial protection and to control clinical signs of 
mycoplasmal pneumonia. 
 
 
 
The inactivated bacterin is concentrated with an ultrafiltration 
and returned to an isotonic concentration with blood by 
diafiltration. Finally, the protector agents (thrimerosal and 
EDTA) and the adjuvant (Carbopol) are added to the final 
product and mixed for 30 minutes. 
 
Clinical test 
Study population: sixty healthy piglets free of M. 
hyopneumoniae, according to routine serological testing and 
study of clinical symptoms, are used in this experiment.  
 
Experimental design: piglets are randomly divided in 3 
groups: vaccinated and challenged with pathogen (G1), non-
vaccinated and challenged (G2) and non-vaccinated and non- 
challenged (G3). Pigs in G1 where vaccinated at 7 days of 
age. Pathogen was administered in pigs in G1 and G2 at 42 
days of age. G3 is used as negative control. Pigs were 
euthanized at the end of the experiment. At necropsy, lung 
samples were taken from both lungs. 
 
Serology: blood samples were collected from all pigs weekly. 
Serum was obtained by centrifugation of blood. These 
samples were tested using a commercial HerdChek M. 
hyopneumoniae indirect ELISA assay (IDEXX Laboratories, 
Westbrook, Maine). 
 
Quantification of M. hyopneumoniae DNA: DNA  was 
extracted from bronchoalveolar lavage fluid (BALF) with the 
QIAamp DNA Mini Kit (Qiagen) and was quantified with a 
real-time PCR with primers based on the ABC transporter 
gene of M. hyopneumoniae. 
 
Average daily weight gain (ADG): pigs are weighed 
periodically. The ADG (gram/pig/ day) is an important factor to 
be determined because M. hyopneumoniae disease has 
almost no mortality but high morbidity and reduction of weight 
gain is the main symptom of infection. 
 
Feed conversion rate (FCR): FCR determines the efficiency of 
the animal in converting feed mass in body mass. It is the 
relation between the average daily feed consumption (AFC) 
and the ADG. 
 
Pathologic examination: macroscopic examination of lungs 
was realized to determine the percentage of lung affected by 
pneumonia (each lobe is assigned with a score according to 
their approximate volume in whole lung). 
Microscopic samples were taken from both lungs and were 
scored from 0 to 4 according  to the severity of pneumonia. 
 
 
 
 
 
 
 
 
Figure 2. Gross pig lung lesion 
scoring system (bars represent 
areas where sections are taken for 
microscopic examination) 
Figure 1. Micrograph of Mycoplasma 
hyopneumoniae attached to ciliated 
epithelium of the respiratory tract 
 
 
Average daily weight gain (ADG) 
Normally, ADG depends on growth stage and it increases as 
time goes (from 0.2 to more than 1 kg per pig per day) until 
pig reaches adulthood. However, all pigs used in this study 
have the same age, so that it should not affect our results 
when comparing different study groups. 
 
 
 
 
 
 
 
 
 
Before inoculation pigs are not infected and all groups should 
grow in a similar way. Once G1 and G2 have been infected, 
both groups will have a reduced weight gain. G3 should gain 
weight faster than G1 and G2.  However, G1 weight gain is 
expected to remain quite similar to G3 while G2 will have a 
more significant weight gain reduction.  
 
Feed conversion rate 
In the same way as ADG, FCR varies with pig’s growth stage, 
but it should not influence the results. FCR results are 
expected to be quite similar to those found  in ADG. 
Pigs in G2 should experience reduced feed intake compared 
with G1 and G3 groups after inoculation. However, FCR will 
be reduced in G2 due to the lower ADG. G1 and G3 should 
remain quite similar between them all over the experiment.  
 
Pathologic examination 
In negative control group (G3), grossly visible pneumonia 
should not be detected in macroscopic examination (it would 
be expected a score near 0). G1 should not present 
macroscopic damage either (at least compared with G2 
pathologic injury). Similar results are expected to be find 
through microscopic examination. 
 
 
Figure 3. Changes in daily 
weight gain from weaning to 
market weight 
 
3. Materials and methods 
 
Vaccine design 
This invention concerns a vaccine comprising a virulent M. 
hyopneumoniae strain, which has been inactivated with 
binary ethyleneimine (BEI), in a suitable amount to produce 
an effective immune protection in pigs using a single dose; 
a physiologically acceptable carrier; and an adjuvant as a 
potentiator of the immune response. 
 
Vaccine production 
M. hyopneumoniae Strain P-5722-3 will be grown in a 
suitable medium for mycoplasma growth. The production 
will be carried out through serially transferred batches until 
a 500 liters fermentation vessel is achieved. 
 
The amount of M. hyopneumoniae is determined by DNA 
fluorometry using a Hoechst 33258 dye solution. 
 
At the end of the growth period, pH is raised to 8.2 and a 
solution of 2-Bromoethylaminehydrobormide (BEA) is 
added. In the presence of the elevated pH, BEA is 
chemically changed to BEI, the inactivating agent. When 
inactivation is finished, BEI generated during inactivation is 
neutralized with sodium thiosulfate. 
 
4. Results 
 
Serology 
It would be expected do not find antibodies against M. 
hyopneumoniae in pigs in the G1 before vaccination because 
in previous studies has been shown that vaccination with 
inactivated M. hyopneumoniae produces an anamnestic 
antibody response, so that pathogen administration is 
necessary to detect serological antibodies. No anti–M. 
hyopneumoniae antibodies should be detected in serum from 
negative control (G3) through all the experiment. In the other 
groups what would be expected to happen, due to the 
administration of the vaccine, is an enhanced humoral 
response of G1 (compared to G2) against M. hyopneumoniae 
once pigs have been challenged with the pathogen. 
 
Quantification of M. hyopneumoniae DNA 
To demonstrate the safety of the vaccine, G1 should not 
show positive results in BALF before inoculation because it 
would mean that vaccine has not been fully inactivated and 
maintains at least part of its virulence. In the same period, G2 
should not show M. hyopneumoniae positive results. G3, as a 
negative control, should not have M. hyopneumoniae infected 
pigs to consider that experimental conditions are controlled. 
In general, should be expected lower levels of M. 
hyopneumoniae DNA  in vaccinated pigs (G1) than those 
challenged but not vaccinated (G2). It would be a 
demonstration of vaccine efficacy. 
5. Conclusions 
 
M. hyopneumoniae infections are spread all over the world 
and cause significant economic losses to the pig industry. In 
this context, it is important to make an effort to improve 
techniques to reduce the infection level and vaccines are an 
important  tool in this field. 
 
The present study has demonstrated the safety and the 
efficacy of this single dose vaccine. This inactivated vaccine 
has created an immune response which is able to control 
clinic symptoms and pulmonary lesions induced by M. 
hyopneumoniae infections. This way, pigs will benefit of an 
increased weight gain and conversion index. Although 
protection is incomplete and the vaccine does not prevent 
colonization, the quantity of microorganism in respiratory tract 
is reduced, as well as the incidence of infection. 
 
In conclusion, vaccination with the designed vaccine in farms 
with significant levels of infection or with emerging clinical 
symptoms is a suitable and economically justified method of 
prevention. 
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